VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics to transform how we treat disease, is pleased to ...

Novo Nordisk A/S NVO and a privately-held biotechnology company, Aspect Biosystems, announced entering a collaboration, development, and license agreement. This will bring together Aspect’s ...

VANCOUVER, British Columbia--(BUSINESS WIRE)--Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics, today announced that it has received a $72.75 ...

Novo Nordisk (NVO) (OTCPK:NONOF) signed a licensing agreement with Canada's Aspect Biosystems to develop bioprinted tissue therapies to replace, repair or supplement biological functions inside the ...

Partnership will leverage Aspect’s proprietary bioprinting technology and Novo Nordisk’s expertise and technology in stem cell differentiation and cell therapy development and manufacturing. Aspect to ...

VANCOUVER, BC and NEW YORK, April 6, 2022 /PRNewswire/ -- Aspect Biosystems ("Aspect"), a biotechnology company developing bioengineered tissue therapeutics to transform how we treat disease, is ...

An Aspect Biosystem scientist at work on a company bioprinter. (Aspect Photo) Vancouver, B.C.-based biotech company Aspect Biosystems inked a partnership worth potentially more than $2.6 billion with ...

Shares of Novo Nordisk A/S (NYSE: NVO) are up over 3.6% on April 12. The immediate catalyst is the announcement of a $2.6 billion collaboration with Aspect Biosystems. But for investors who have been ...